ArticleNanoscale research letters2020
Functionalized Folate-Modified Graphene Oxide/PEI siRNA Nanocomplexes for Targeted Ovarian Cancer Gene Therapy.
Article in Nanoscale research letters, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 71 citations in OpenAlex.
- Plant-Derived Vesicle-like Nanoparticles for Cancer Therapy: From Drug Delivery to Combined Immunotherapy.Antioxidants (Basel, Switzerland) · 2026Review
- Recent Advances in Integrating Graphene into Polymeric Nanocomposite Hydrogels for Biomedical Applications.Macromolecular bioscience · 2026Review
- Comparative biodegradation of functionalized graphene oxide nanosheets by myeloperoxidase and neutrophil extracellular traps.Frontiers in bioengineering and biotechnology · 2026Article
- Dual Graphene Oxide-Based Multigene Delivery for Cancer Elimination via Stromal and Immune Reprogramming.International journal of biomaterials · 2026Article
- Engineered plant extracellular vesicles: Emerging nanoplatforms for combinational cancer immunotherapy.Acta pharmaceutica Sinica. B · 2025Review
- Interplay between material properties and cellular effects drives distinct pattern of interaction of graphene oxide with cancer and non-cancer cells.Journal of nanobiotechnology · 2025Article
- Stimuli-responsive Graphene-polysaccharide Nanocomposites for Drug Delivery and Tissue Engineering.Current organic synthesis · 2025Review
- A highly biocompatible polyethyleneimine/sulfonated polysulfone hemoperfusion microsphere with tailored surface charge for rapid and efficient removal of major protein-bound uremic toxins from simulated human plasma.Regenerative biomaterials · 2025Article
- Advances in Parenteral Nanocarriers and Delivery Devices: A Comprehensive Review.Current pharmaceutical design · 2025Review
- Advancing cancer treatments: The role of oligonucleotide-based therapies in driving progress.Molecular therapy. Nucleic acids · 2024Review
- Graphene Oxide Nanoparticles and Organoids: A Prospective Advanced Model for Pancreatic Cancer Research.International journal of molecular sciences · 2024Review
- Slow-sculpting graphene oxide/alginate gel loaded with platelet-rich plasma to promote wound healing in rats.Frontiers in bioengineering and biotechnology · 2024Article
- The influence of protein corona on Graphene Oxide: implications for biomedical theranostics.Journal of nanobiotechnology · 2023Review
- Cancer Therapeutic siRNA Delivery and Imaging by Nitrogen- and Neodymium-Doped Graphene Quantum Dots.ACS biomaterials science & engineering · 2023Article
- Repair of critical-sized bone defects in rabbit femurs using graphitic carbon nitride (g-CScientific reports · 2023Article
- Elimination of Cancer Cells in Co-Culture: Role of Different Nanocarriers in Regulation of CD47 and Calreticulin-Induced Phagocytosis.ACS applied materials & interfaces · 2023Article
- Article
- Stimuli-responsive nanoformulations for CRISPR-Cas9 genome editing.Journal of nanobiotechnology · 2022Review
- Characteristics of Graphene Oxide for Gene Transfection and Controlled Release in Breast Cancer Cells.International journal of molecular sciences · 2022Review
- Polyethyleneimine (PEI) as a Polymer-Based Co-Delivery System for Breast Cancer Therapy.Breast cancer (Dove Medical Press) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Gene therapy is emerging as a valid method for the treatment of ovarian cancer, including small interfering RNA (siRNA). Although it is so powerful, few targeting efficient gene delivery systems seriously hindered the development of gene therapy. In this study, we synthesized a novel gene vector PEG-GO-PEI-FA by functionalized graphene oxide (GO), in which folic acid (FA) can specifically bind to the folate receptor (FR), which is overexpressed in ovarian cancer. Characterizations of the nanocomplexes were evaluated by dynamic light scattering (DLS), atomic force microscopy (AFM), and Fourier transform infrared spectroscopy (FTIR). The siRNA condensation ability and stability were assessed by agarose gel electrophoresis. Cellular uptake efficiency and lysosomal escape ability in ovarian cancer cells were investigated by confocal laser scanning microscopy. Furthermore, cellular biosafety of the system and inhibitory of the siRNA tolerability were evaluated by CCK-8 assay. The size of the PEG-GO-PEI-FA nanocomplexes was 216.1 ± 2.457 nm, exhibiting mild cytotoxicity in ovarian cancer cells. With high uptake efficiency, PEG-GO-PEI-FA can escape from the lysosome rapidly and release the gene. Moreover, PEG-GO-PEI-FA/siRNA can effectively inhibit the growth of ovarian cancer cells. By and large, the PEG-GO-PEI-FA/siRNA may offer a promising strategy for siRNA delivery in the treatment of FR-positive ovarian carcinoma or similar tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.